Emilia Filipczyk−Cisarż

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Andrés Poveda, Ignace Vergote, Sergei Tjulandin et al. · Annals of Oncology · 2010 · 168 citations · Full text

Medicine, Oncology, Pharmacology +15

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Stuart Kaye, Nicoletta Colombo, B.J. Monk et al. · Annals of Oncology · 2010 · 59 citations · Full text

Medicine, Oncology, Pharmacology +15

Evaluation of the Toxicity of AnticancerChemotherapy in Patients with Colon Cancer

Anna Wiela−Hojeńska, T Kowalska, Emilia Filipczyk−Cisarż et al. · Advances in Clinical and Experimental Medicine · 2015 · 34 citations · Full text

Medicine, Pharmacology, Cancer Drug Toxicity Management +12

Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.

A. Poveda, S. Tjulandin, Beihua Kong et al. · Journal of Clinical Oncology · 2010 · 12 citations

Medicine, Oncology, Chemotherapy +16

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

Mateusz Malik, Maciej Michalak, Barbara Radecka et al. · Journal of Clinical Medicine · 2021 · 10 citations · Full text

Medicine, Oncology, Pharmacology +14